Q3 2023 BioInvent International AB Earnings Call Transcript
Thank you very much, and welcome, everybody, to our call today. It's the interim report, January to September 2023. I am Martin Welschof, the CEO, and I will start the presentation. Later, the second part of the presentation will be covered by Stefan Ericsson, our CFO.
I would start with a quick summary of the interim report, so briefly go over the events in the third quarter. So we had the first patient recruited into our Phase A (sic - see Presentation, slide 2, "Phase 2a") trial of single-agent BI-1808 for the treatment of advanced malignancies. That was a very important milestone for the company, and I will come back to that later in a little bit more detail.
Then we also initiated the subcutaneous arm of our Phase 1/2 clinical trial for solid tumors for BI-1206 in combination with pembrolizumab.
Then on the collaboration side, as you probably will remember, we're quite active on that as well. So we have signed the agreement with Exelixis and actually achieved the first research milestone, which was triggering a USD1
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |